Lantern Pharma (LTRN) Income from Non-Controlling Interests (2020 - 2022)

Lantern Pharma (LTRN) has 3 years of Income from Non-Controlling Interests data on file, last reported at $4.1 million in Q1 2022.

• Quarterly Income from Non-Controlling Interests rose 68.11% year-over-year to $4.1 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $14.0 million (changed N/A YoY) and the FY2021 annual result came in at $12.4 million, up 109.26% from the prior year.
• Income from Non-Controlling Interests advanced to $4.1 million in Q1 2022, from $3.5 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $4.1 million in Q1 2022 to a low of $1.7 million in Q3 2020.
• A 3-year average of $3.0 million and a median of $2.9 million in 2020 frame the typical range for Income from Non-Controlling Interests.
• The widest YoY moves for Income from Non-Controlling Interests: up 138.33% in 2021, down 22.24% in 2021.
• Tracing LTRN's Income from Non-Controlling Interests over 3 years: stood at $2.9 million in 2020, then rose by 22.24% to $3.5 million in 2021, then rose by 16.44% to $4.1 million in 2022.
• The last three Income from Non-Controlling Interests figures came in at $4.1 million (Q1 2022), $3.5 million (Q4 2021), and $4.1 million (Q3 2021), per Business Quant data.